Back to all webinars
Initiation of treatment for Waldenström’s macroglobulinemia: Practical guidance for starting treatment and managing complications
Véronique Leblond, Meletios Dimopoulos, Ramón García-Sanz and Wojciech Jurczak outline the topic of treatment initiation for Waldenström’s macroglobulinemia, exploring treatment options, monitoring, and unmet needs.
Speakers
How do I treat patients with Waldenström's macroglobulinemia?
Fast-forward to:
Asymptomatic Waldenstöm's macroglobulinemia: Definition and risk assessment
61700840e1951d0588524cce
When should treatment be initiated for Waldenström’s macroglobulinemia?
617008ce9787be057b8f8681
Symptomatic patient prognosis for with Waldenström’s macroglobulinemia
61a0a3c21b44ef0dbc707b16
Assessing whether a patient with WM is fit or unfit
61a0b5de1b44ef0dbc707b2b
An overview of first-line treatment options for Waldenström’s macroglobulinemia
61adf2892fc9050db56f8251
Challenges posed by first-line treatment for Waldenström’s macroglobulinemia
61addad9f8742a0daf9e2e11
Case study
Fast-forward to:
A young male (41 years of age) with symptomatic WM initially treated with bortezomib, dexamethasone and rituximab.
616e86d3b38dcf058767fee9
An older female (81 years of age) with symptomatic WM and comorbid type 2 diabetes initially treated with ibrutinib.
616e89717229d4059475b88b
Open panel discussion
Fast-forward to:
When should we initiate treatment in the COVID era?
61ade5de2fc9050db56f8114
How do we identify patients appropriate for chemotherapy-free treatment?
61ade7162fc9050db56f812e
How do we manage the risk of treatment-related complications?
61ade7e0f8742a0daf9e2e53
How do we define and treat “unfit” versus “fit” patients?
61ade90c2fc9050db56f8140
What is the impact of MYD88/CXCR4 mutation status in first-line treatment?
61ade9e41b44ef0dbc708729
Debate
No entries
Q&A
Fast-forward to:
Would you treat a patient with WM who presents with high monoclonal component (IgM = 8.5 g/dL), mild anemia (Hb = 10.5 g/dL), and no signs of hyperviscosity?
61adee93f8742a0daf9e2f50
How long do you wait before deciding that a patient is refractory or suboptimally responding to therapy?
61adef1d3ebc500dae6c8e91